Clinical Trials Logo

Filter by:
NCT ID: NCT04566601 Completed - Clinical trials for Borderline Personality Disorder

A Study to Test Different Doses of BI 1358894 and Find Out Whether They Reduce Symptoms in People With Borderline Personality Disorder

Start date: November 13, 2020
Phase: Phase 2
Study type: Interventional

This study is open to adults with borderline personality disorder. The purpose of this study is to find out whether a medicine called BI 1358894 helps to reduce symptoms in people with borderline personality disorder. Four different doses of BI 1358894 are tested in the study. Participants are put into 5 groups by chance. Participants in 4 of the 5 groups take different doses of BI 1358894. Participants in the fifth group take placebo. Participants take BI 1358894 and placebo as tablets once a day. Placebo tablets look like BI 1358894 tablets but do not contain any medicine. Participants are in the study for about 5 months. During this time, they visit the study site about 12 times and get about 6 phone calls. At the visits, doctors ask participants about their symptoms. The results between the BI 1358894 groups and the placebo group are then compared. The doctors also regularly check the general health of the participants.

NCT ID: NCT04564404 Completed - Survey, Financial Clinical Trials

Neuromusculaire Monitoring Survey

Start date: November 10, 2021
Phase: N/A
Study type: Interventional

This survey aims to better define the willingness-to-buy for Applications in Neuromuscular Monitoring throughout European hospitals.

NCT ID: NCT04563468 Completed - Clinical trials for Diaphragmatic Paralysis

Effects of Inspiratory Muscle Training on Exertional Breathlessness in Patients With Unilateral Diaphragm Paralysis

Start date: January 6, 2018
Phase: N/A
Study type: Interventional

Treatment options for unilateral diaphragm paralysis are limited. Diaphragmatic plication via mini thoracotomy is sometimes considered in the University Hospital Leuven if severe symptoms persist for longer than 12 months after initial diagnosis. Preliminary data indicate that daily inspiratory muscle strength and endurance training can lead to increased nondiaphragmatic inspiratory muscle recruitment and help those with symptoms from diaphragmatic paralysis. Randomized controlled trials comparing intervention groups with improvements achieved by natural recovery in the first months after diagnosis are however so far lacking. The objective of the current study is therefore to investigate the effects of daily inspiratory muscle training in the first 6 months following diagnosis of unilateral diaphragmatic paralysis. The investigators hypothesize that respiratory muscle training in symptomatic patients with UDP (in comparison with a control group) will reduce symptoms of exertional dyspnea (primary outcome) and will improve respiratory muscle function (at rest and during exercise) and pulmonary function (sitting and supine).

NCT ID: NCT04563026 Completed - Alcoholic Hepatitis Clinical Trials

A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment

AHFIRM
Start date: January 22, 2021
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, phase 2b clinical Trial evaluating Safety and Efficacy of DUR-928 (an experimental medication) in Patients with Alcoholic Hepatitis (AH).

NCT ID: NCT04562155 Completed - Clinical trials for Refractory and/or Unexplained Chronic Cough

Clinical Study to Evaluate the Efficacy and Safety of Three Different Doses of BAY1817080 Compared to Placebo in Patients With Chronic Cough

PAGANINI
Start date: October 2, 2020
Phase: Phase 2
Study type: Interventional

Researchers in this study want to find the optimal therapeutic dose of drug BAY1817080 for patients with long-standing cough with or without clear causes (refractory and/or unexplained chronic cough, RUCC). Study drug BAY1817080 is a new drug under development for the treatment of long-standing cough. It blocks proteins that are expressed by the airway sensory nerves which are oversensitive in patients with long-standing cough. This prevents the urge to cough. Researchers also want to learn the safety of the study drug and how well it works in reducing the cough frequency, severity and urge-to-cough. Participants in this study will receive either the study drug or placebo (a placebo looks like the test drug but does not have any medicine in it) tablets twice daily for 12 weeks. Observation for each participant will last about 18 weeks in total. Participants will be asked to wear a digital device to record the cough and to complete questionnaires every day to document the symptoms. Blood samples will be collected from the participants to monitor the safety and measure the blood level of the study drug.

NCT ID: NCT04559386 Completed - Survey, Usability Clinical Trials

Neuromusculaire Monitoring Survey - Usability

Start date: November 10, 2021
Phase: N/A
Study type: Interventional

This survey aims to better define Anesthesiologist's perceived usability of existing anesthesia Neuromuscular Monitoring devices.

NCT ID: NCT04556162 Completed - Cystic Fibrosis Clinical Trials

Evaluation of Salt Status in Patients With Cystic Fibrosis

Start date: January 1, 2018
Phase:
Study type: Observational

The results of the annual check-up will be collected to evaluate the best urinary marker for fractional sodium excretion and salt status will be correlated to clinical outcome measures.

NCT ID: NCT04553289 Completed - Clinical trials for Shoulder Impingement Syndrome

Exercise Into Pain in Subacromial Shoulder Pain

Start date: July 30, 2020
Phase: N/A
Study type: Interventional

The aim of the randomized clinical trial is to investigate if "exercising into pain" gives better results in term of clinical outcomes compared to a non-painful exercise program.

NCT ID: NCT04552847 Completed - Clinical trials for Neuroendocrine Tumors

Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors

Start date: October 7, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

The aim of this study is to evaluate the diagnostic performance of Al18F-NOTA-octreotide PET imaging in comparison with the current golden standard, 68Ga-DOTA-somatostatin analog PET, in neuroendocrine tumor patients.

NCT ID: NCT04552197 Completed - Healthy Clinical Trials

A Study of JNJ-64251330 in Healthy Participants

Start date: September 2, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate: systemic and local gut (rectum and sigmoid colon) exposure to JNJ-64251330, local tissue Pharmacodynamics (PD) using gut (rectum and sigmoid colon) biopsies (Part 1) and the effect of food on the rate and extent of absorption of JNJ-64251330 from oral tablet dosed with or without food (Part 2).